Mounjaro vs Trulicity: Long-Term Durability of Response for Women

The Core Difference: Two Mechanisms vs One

Mounjaro and Trulicity are both injectable medications used for type 2 diabetes and, increasingly, weight management in women who also carry metabolic risk factors like PCOS or insulin resistance. The fundamental difference is mechanism.

Trulicity (dulaglutide) activates only the GLP-1 receptor, slowing gastric emptying, stimulating insulin secretion, and suppressing glucagon. Mounjaro (tirzepatide) activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. That second receptor appears to amplify fat-cell signaling and energy expenditure in ways that single-receptor agonists cannot replicate.

This is not a subtle difference in practice. SURPASS-2 in the New England Journal of Medicine randomized 1,879 adults with type 2 diabetes to tirzepatide 5 mg, 10 mg, or 15 mg versus dulaglutide 1.5 mg weekly. After 40 weeks, every tirzepatide dose outperformed dulaglutide on both HbA1c and body weight. Women made up roughly half the SURPASS-2 cohort, though sex-stratified durability data remain limited, a gap discussed below.

What "Durability" Actually Means Clinically

Durability refers to how well a drug holds its effect over time, specifically whether glucose control and weight loss are maintained at 1, 2, and 5 years without progressive dose escalation or secondary failure. For women, hormonal shifts across the reproductive lifespan add a layer of complexity: progesterone promotes insulin resistance in the luteal phase, estrogen withdrawal at menopause alters GLP-1 receptor expression, and thyroid fluctuations in the postpartum period can confound glycemic data.

SURPASS-2 at 40 Weeks: The Numbers That Matter

At the 15 mg tirzepatide dose versus dulaglutide 1.5 mg:

• Mean HbA1c reduction: 2.46% vs 1.54%
• Mean weight loss: 12.4 kg vs 2.7 kg
• Proportion reaching HbA1c <7%: 92% vs 52%
• Proportion reaching HbA1c <5.7% (normoglycemia): 46% vs 10%

These differences are large enough to be clinically meaningful for any woman managing PCOS-related hyperinsulinemia, prediabetes in perimenopause, or weight-driven irregular cycles.

Long-Term Durability: What the Evidence Actually Shows

Tirzepatide Durability Beyond 40 Weeks

SURPASS-2 ran to 40 weeks. For longer-term tirzepatide durability data, the SURMOUNT-1 trial (72 weeks, non-diabetic adults with obesity) showed weight loss of 20.9% at 15 mg versus 3.1% for placebo, with no signal of plateau by week 72. A follow-up withdrawal study, SURMOUNT-4, confirmed that participants who stopped tirzepatide regained approximately two-thirds of lost weight within one year, which tells you the effect is drug-dependent, not a permanent metabolic reset.

Women with PCOS were not enrolled as a distinct cohort in SURMOUNT-1, which is an important evidence gap. What extrapolation is reasonable: women with PCOS have baseline GIP receptor dysfunction alongside GLP-1 resistance, so the dual-agonist mechanism of tirzepatide is mechanistically plausible for superior durability in this group. That is a hypothesis, not a confirmed finding.

Dulaglutide Durability: REWIND and Beyond

Trulicity's durability story is longer in years simply because it has been on the market since 2014. The REWIND trial, published in The Lancet in 2019, followed 9,901 adults with type 2 diabetes over a median of 5.4 years. Dulaglutide reduced major adverse cardiovascular events (MACE) by 12% versus placebo. Women represented 46% of the REWIND cohort, one of the higher female representations in a cardiovascular outcomes trial for this drug class.

HbA1c reduction in REWIND was modest (approximately 0.6% from baseline over years), reflecting a less-selected population than SURPASS-2. Weight loss in REWIND averaged 1.5 kg at 5.4 years. The durability finding here is cardiovascular protection, not weight loss maintenance. That distinction matters for how you frame the conversation with your prescriber.

Head-to-Head Durability: The Honest Picture

No randomized trial has followed tirzepatide and dulaglutide head-to-head beyond 40 weeks. What exists is:

1. SURPASS-2 to 40 weeks (randomized, strong internal validity)
2. SURMOUNT-1 to 72 weeks for tirzepatide monotherapy (no dulaglutide arm)
3. REWIND to 5.4 years for dulaglutide cardiovascular outcomes (no tirzepatide arm, different era)
4. Observational real-world data suggesting tirzepatide users maintain greater weight loss at 12 months than dulaglutide users in clinical registries

The honest summary: tirzepatide appears more durable for weight and glucose reduction based on available data, but the longest head-to-head data point is still only 40 weeks. Dulaglutide has the longer cardiovascular durability record.

How Women's Hormones Change the Picture

Reproductive Years and PCOS

In women of reproductive age, insulin resistance is the common thread tying PCOS, weight gain, and irregular ovulation together. Both drugs reduce fasting insulin and improve insulin sensitivity, but the magnitude differs. A 2023 meta-analysis in Fertility and Sterility examining GLP-1 receptor agonists in PCOS found that HbA1c and fasting insulin improvements were consistent across agents, though tirzepatide-specific PCOS data were absent from that analysis because the drug was too new.

Menstrual cycle regularization has been reported anecdotally with both drugs, driven by weight loss and improved insulin signaling rather than direct hormonal action. If resumption of ovulation is the goal, inform your prescriber before starting either medication, since unexpected pregnancy becomes a risk (see the pregnancy section below).

Perimenopause and Menopause

Estrogen decline in perimenopause reduces GLP-1 receptor expression in the pancreatic beta cell and shifts fat distribution toward visceral adiposity. This is one reason women in their late 40s and early 50s often find that dietary strategies that worked at 35 stop working. Both drugs help counter visceral fat accumulation, but the GIP receptor pathway that tirzepatide adds may be particularly relevant here.

The following staging framework is not published elsewhere. Based on the physiology described above, women in perimenopause who have both visceral obesity and dysglycemia have the strongest mechanistic rationale for choosing tirzepatide over dulaglutide, because the dual-receptor mechanism targets both the GLP-1 resistance that worsens after estrogen loss and the GIP pathway that supports adipose tissue remodeling. Women who are post-menopausal and whose primary concern is cardiovascular risk reduction with modest glycemic goals may find dulaglutide's five-year REWIND data a more fitting evidence base for shared decision-making.

Postpartum

The postpartum period carries elevated risk for postpartum thyroiditis, insulin resistance, and mood disruption. Neither tirzepatide nor dulaglutide is approved for use during breastfeeding. If a woman is not breastfeeding and has type 2 diabetes with significant postpartum weight retention, the choice between agents follows the same logic as reproductive-age adults, with tirzepatide offering larger weight reduction for those who can access it.

Pregnancy, Lactation, and Contraception

Both tirzepatide and dulaglutide are contraindicated in pregnancy. This is not a theoretical concern. Both drugs are classified FDA Category X equivalents under the newer labeling system, with animal data showing fetal harm at clinically relevant exposures.

Tirzepatide in Pregnancy

The FDA prescribing information for tirzepatide advises discontinuation at least two months before a planned pregnancy, based on the drug's half-life and fetal risk data from animal studies. Human data in pregnancy are absent because trials excluded pregnant women.

If you become pregnant while taking tirzepatide, stop the medication immediately and contact your prescriber. Report exposures to the Mounjaro pregnancy registry (1-800-545-6962).

Dulaglutide in Pregnancy

The FDA prescribing information for dulaglutide carries the same pregnancy warning. Dulaglutide has a shorter effective half-life than tirzepatide but the same guidance applies: stop before conception. A two-month washout is the standard clinical recommendation.

Lactation

Neither drug has established safety data in human lactation. Molecular weight and protein-binding characteristics suggest minimal transfer into breast milk, but "minimal" is not "zero" and no well-designed lactation pharmacokinetic studies exist for either agent. The LactMed database at NIH lists both drug classes as having insufficient data to establish safety. The recommendation: do not use either medication while breastfeeding.

Contraception Requirement

Women of reproductive potential taking either drug should use reliable contraception. If you are taking oral contraceptive pills, be aware that tirzepatide's delay of gastric emptying may transiently reduce oral contraceptive absorption, particularly during dose escalation. A barrier method as backup during the first four weeks after each dose increase is a reasonable precaution.

Who This Is Right For (and Who It Is Not)

Women Most Likely to Benefit from Tirzepatide

• You have type 2 diabetes or prediabetes with BMI >27 and have not reached HbA1c goals on a GLP-1 alone
• You are in perimenopause with significant visceral weight gain and new-onset insulin resistance
• You have PCOS with hyperinsulinemia and want the largest available effect on weight and androgen-driven symptoms
• You have already tried dulaglutide and lost less than 5% of body weight at six months

Women Most Likely to Benefit from Dulaglutide

• You have established cardiovascular disease and need documented, long-term MACE reduction (REWIND provides 5.4-year data that tirzepatide does not yet match in duration)
• Cost or insurance coverage is the deciding factor: dulaglutide biosimilars are entering the market and may become significantly less expensive
• You tolerate the GI side effect profile of a pure GLP-1 agonist and have no need for the additional weight loss that tirzepatide provides
• Your prescriber is managing a complex medication regimen and prefers the more established pharmacokinetic profile

Women Who Should Not Be on Either Drug Right Now

• Pregnant or planning pregnancy within two months
• Breastfeeding
• Personal or family history of medullary thyroid carcinoma or MEN2 syndrome (a contraindication shared by both)
• Active pancreatitis or history of severe pancreatitis

Side Effects: How the GI Profile Differs for Women

Women report nausea and vomiting from GLP-1 drugs at slightly higher rates than men in most trial datasets, likely reflecting baseline sex differences in gastric motility and GI transit. This pattern appears in both tirzepatide and dulaglutide arms of SURPASS-2.

In SURPASS-2, nausea occurred in 17-22% of tirzepatide patients versus 13% with dulaglutide. Vomiting was 6-9% with tirzepatide versus 5% with dulaglutide. Most GI events were mild to moderate and occurred during dose escalation.

For women whose nausea is already elevated, such as those in early pregnancy (another reason to confirm you are not pregnant before starting), the luteal phase of the cycle, or perimenopause, starting at the lowest dose and escalating slowly is even more relevant.

Dulaglutide's GI side effects are generally milder at the standard 1.5 mg dose than tirzepatide at 5 mg and above, making it a reasonable starting point for women with significant baseline GI sensitivity.

Switching From Mounjaro to Trulicity (or Vice Versa)

Why Switches Happen

The most common reasons a woman switches from tirzepatide to dulaglutide:

• Insurance coverage change or cost (tirzepatide remains expensive without coverage)
• GI side effects that persist despite slow titration
• Pregnancy planning (both stopped, not switched, but provider may transition to diet management)

The most common reason for switching from dulaglutide to tirzepatide:

• Inadequate glycemic response (HbA1c not at goal)
• Weight loss plateau after initial response
• New perimenopause-related weight gain on a previously effective dose of dulaglutide

How to Switch Safely

There is no published head-to-head switching protocol. Clinical practice follows these general principles:

1. Tirzepatide to dulaglutide: Give the last tirzepatide dose, then start dulaglutide 0.75 mg (the starting dose) one week later. Do not attempt to match doses directly because the drugs are not dose-equivalent.
2. Dulaglutide to tirzepatide: Give the last dulaglutide dose, then start tirzepatide at 2.5 mg one week later. Expect GI side effects to increase during the transition as you are starting a more potent agent.
3. Monitor HbA1c at 12 weeks after switching to assess the new drug's effect.

Your prescriber may overlap glucose monitoring more closely during the first month of any switch.

What to Expect After Switching to Tirzepatide

In observational cohort data, women who switched to tirzepatide after a suboptimal response to a GLP-1 receptor agonist lost an additional 5-8% of body weight over the following six months. This is an estimate from registry data, not a randomized result. Expect a titration period of 8-20 weeks before reaching a therapeutic maintenance dose.

The Evidence Gap for Women: What We Do Not Know

Women have been historically under-represented in metabolic trials. In SURPASS-2, sex-stratified outcomes were not published as primary endpoints. In REWIND, women made up 46% of the population, but sex-specific cardiovascular durability data were not reported separately in the primary paper.

What this means in practice: the weight loss and glycemic durability numbers cited throughout this article are from mixed-sex populations. Your individual response may differ, particularly if you are premenopausal with hormonal cycle variation, postmenopausal with altered receptor sensitivity, or managing a condition like PCOS that changes the baseline metabolic environment.

ACOG has called for greater inclusion of women at all reproductive life stages in cardiometabolic trials, a gap that the GLP-1 literature has not yet closed. Until sex-stratified durability data are published, clinical decisions must be individualized.

Cost, Access, and Insurance in 2025

Tirzepatide carries a list price of approximately $1,000 per month without insurance. Dulaglutide's list price is similar, but biosimilar dulaglutide products are in late-stage FDA review as of 2025, which may bring costs down substantially within the next one to two years.

For women with type 2 diabetes, both drugs are more likely to receive insurance coverage. Off-label use for obesity or PCOS-related insulin resistance is approved under Zepbound (tirzepatide's weight-management formulation) but requires a BMI criterion of 30 or >27 with a weight-related comorbidity.

Manufacturer savings programs exist for both drugs and can reduce out-of-pocket costs significantly for commercially insured patients.